Romosozumab
Based on 1 publication(s) in Google Scholar
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.11%
- CAS No.: 909395-70-6
- Masse moléculaire:146.32 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
SOST/Sclerostin
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male cynomolgus monkeys[1]
-
Dosage:30 mg/kg
-
Administration:Subcutaneous injection; 30 mg/kg twice a week for 10 weeks
-
Result:Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized SOST Protein, Human can bind Romosozumab. The EC50 for this effect is 12.46 ng/mL.
Product Details
-
CAS No. 909395-70-6
-
Accession Q9BQB4
-
Synonyms AMG-785; CDP-7851
-
Masse moléculaire 146.32 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG2 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG2 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Pureté
99.11%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Livraison
Shipping with dry ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Schisandrol B inhibits osteoclastogenesis and mitigates estrogen deficiency-induced bone loss by targeting TRAF6-NOX1 pathway. [Abstract]2026 Jan:150:157669. PMID: 41435606
Romosozumab purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2026 Jan:150:157669. [Abstract]
Representative images of mature OCs (nuclei≥3) treated with SolB, Denosumab, and Romosozumab (5 μM) and quantitation of mature OCs.
Pureté et documentation
Références
[1]. Paik J, Scott LJ. Romosozumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2020 Nov;37(11):845-855. [Content Brief]
[2]. Ominsky MS, et al. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys. J Bone Miner Res. 2017 Apr;32(4):788-801. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)